SUMO - a post-translational modification with therapeutic potential?

Title
SUMO - a post-translational modification with therapeutic potential?
Author(s)
우창훈주니치 아베[주니치 아베]
Keywords
NF-KAPPA-B; STAT1-MEDIATED GENE ACTIVATION; SIGNAL-REGULATED KINASE-5; CONDUCTION-SYSTEM DISEASE; ENDOTHELIAL-CELLS; TRANSCRIPTIONAL ACTIVATION; CARDIOMYOCYTE APOPTOSIS; DILATED CARDIOMYOPATHY; MOUSE DEVELOPMENT; UBIQUITIN LIGASE
Issue Date
201004
Publisher
ELSEVIER SCI LTD
Citation
CURRENT OPINION IN PHARMACOLOGY, v.10, no.2, pp.146 - 155
Abstract
Sumoylation is a covalent modification, which is mediated by small ubiquitin-like modifier (SUMO) polypeptides. A growing body of evidence has shown that sumoylation affects the functional properties of many substrates in the regulation of cellular processes. Recent reports indicate the crucial role of sumoylation in human diseases including familial dilated cardiomyopathy, suggesting that targeting of sumoylation would be of considerable interest for novel therapies. Even though hundreds of SUMO substrates have been identified, their pathophysiological roles remain to be determined. Among them, ERK5-sumoylation has recently been linked to diabetes and implicated in endothelial dysfunction and cardiomyocyte apoptosis in vivo. These findings support the idea that ERK5-sumoylation is a novel therapeutic target for the treatment of diabetes-related cardiovascular diseases.
URI
http://hdl.handle.net/YU.REPOSITORY/22622http://dx.doi.org/10.1016/j.coph.2009.12.001
ISSN
1471-4892
Appears in Collections:
의과대학 > 약리학교실 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE